Scoring Methodology
This page provides the technical detail on how Legit.Health computes the ASCORAD (automated SCORAD) and aEASI (automated EASI) scores for atopic dermatitis, from image input through to the final severity value.
The SCORAD formula
SCORAD (SCORing Atopic Dermatitis) is a composite measure comprising three components:
where:
- = Extent (affected body surface area, 0–100%)
- = Intensity (sum of six sign scores, each 0–3; total 0–18)
- = Subjective symptoms (pruritus NRS 0–10 + sleep disturbance NRS 0–10; total 0–20)
The maximum SCORAD is 103. The objective SCORAD (A/5 + 7B/2) has a maximum of 83, and this is what the AI computes. Subjective symptoms are patient-reported.
BSA estimation (component A)
How the AI measures affected area
A deep learning segmentation model (DeepLabV3+ architecture) analyses each body area photograph and classifies each pixel as:
- Affected skin (eczematous lesion)
- Unaffected skin (normal or uninvolved)
- Non-skin (background, clothing, hair)
The percentage of affected skin relative to total visible skin area is computed per photograph. These per-image percentages are combined across all captured body areas using anatomical weighting to produce the total BSA (0–100%).
Why pixel-level BSA matters
In manual SCORAD, the BSA component is estimated using the "rule of nines" — a coarse visual estimation method. This is the single largest source of inter-rater variability in SCORAD scoring. Pixel-level segmentation replaces this estimation with an objective measurement, eliminating the most variable component of the manual score.
Intensity scoring (component B)
Six clinical signs
Each sign is scored on a 0–3 ordinal scale at the representative affected area:
| Score | Meaning |
|---|---|
| 0 | Absent |
| 1 | Mild |
| 2 | Moderate |
| 3 | Severe |
The six signs and how the AI scores each:
| Sign | Description | AI methodology |
|---|---|---|
| Erythema | Redness of affected skin | Colour analysis calibrated to skin type, boundary detection |
| Oedema/papulation | Swelling and raised papules | Surface texture and topology analysis from image features |
| Oozing/crusts | Weeping or crusted lesions | Specific visual feature detection for wet/crusted surfaces |
| Excoriations | Scratch marks from pruritus | Linear pattern recognition for scratch marks |
| Lichenification | Thickened, leathery skin from chronic scratching | Texture classification for thickened skin patterns |
| Dryness | Xerosis of uninvolved skin | Surface appearance analysis compared to normal skin texture |
The intensity total is the sum of all six sign scores (0–18).
Severity thresholds
| SCORAD range | Severity classification |
|---|---|
| 0–24 | Mild |
| 25–50 | Moderate |
| >50 | Severe |
These thresholds are the standard SCORAD severity bands used in clinical trials.
EASI scoring
The Eczema Area and Severity Index (EASI) is a co-accepted primary efficacy measure for AD, alongside SCORAD. EASI scores four signs (erythema, induration/papulation, excoriation, lichenification) across four body regions, each weighted by regional BSA.
| EASI range | Severity classification |
|---|---|
| 0–1 | Clear |
| 1–7 | Mild |
| 7–21 | Moderate |
| >21 | Severe |
SCORAD vs. EASI: when to use which
| Aspect | SCORAD | EASI |
|---|---|---|
| Subjective component | Yes — pruritus + sleep NRS (patient-reported) | No — purely objective |
| Scale | 0–103 (objective 0–83) | 0–72 |
| Body regions | Whole body + representative lesion area | 4 defined regions (head, trunk, upper/lower limbs) |
| Validation status | Published (JID Innovations 2022) | Ongoing (aEASI_HVN study) |
| Regulatory acceptance | FDA and EMA accepted | FDA and EMA accepted |
Both SCORAD and EASI are fully supported by the Legit.Health platform. The choice is made during protocol design based on sponsor preference, prior precedent in the indication, and regulatory strategy.
Manual vs. automated scoring
| Aspect | Manual (SCORAD/EASI) | Automated (ASCORAD/aEASI) |
|---|---|---|
| BSA estimation | Visual "rule of nines" (±15–20% variability) | Pixel-level segmentation (objective) |
| Sign scoring | Subjective 0–3 per sign | AI-computed 0–3 per sign, calibrated against expert consensus |
| Reproducibility | Inter-rater variability across sites | Identical score for identical image, every time |
| Time per assessment | 5–10 minutes (manual scoring) | <2 seconds (AI processing) |
| Subjective symptoms | Patient-reported (SCORAD only) | Patient-reported (unchanged; EASI has no subjective component) |
| Training required | Calibration exercises across sites | None (AI is the rater) |